Abstract
Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Current Pharmaceutical Design
Title: The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Volume: 15 Issue: 1
Author(s): Christine L. Miller
Affiliation:
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Abstract: Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Export Options
About this article
Cite this article as:
Miller L. Christine, The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185805
DOI https://dx.doi.org/10.2174/138161209787185805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Medicinal Chemistry Studies of Neglected Diseases)
Mini-Reviews in Medicinal Chemistry Subject Index To Volume 8
Current Pharmaceutical Design Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews Safety Issues of Vitamin D Supplementation
Anti-Cancer Agents in Medicinal Chemistry PET Imaging for Gene & Cell Therapy
Current Gene Therapy Patent Selections
Recent Patents on Anti-Infective Drug Discovery Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Synthesis and SAR Study of Simple Aryl Oximes and Nitrofuranyl Derivatives with Potent Activity Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics Priority Strategies for Sustainable Fight Against HIV/AIDS in Low-Income Countries
Current HIV Research Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Preface
Recent Patents on Anti-Infective Drug Discovery The Professional Phagocyte Dictyostelium discoideum as a Model Host for Bacterial Pathogens
Current Drug Targets QSAR Modeling for Quinoxaline Derivatives using Genetic Algorithm and Simulated Annealing Based Feature Selection
Current Medicinal Chemistry MRSA Infections: From Classical Treatment to Suicide Drugs
Current Medicinal Chemistry Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member:
Current HIV Research